Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
David T Yeung(Royal Adelaide Hospital), On Behalf of the ALLG(Australasian Leukaemia and Lymphoma Group), Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Kathryn Jackson(Nambour General Hospital), Naranie Shanmuganathan(South Australia Pathology), Philip Rowling(Calvary Mater Newcastle Hospital), David M. Ross(Flinders Medical Centre), Timothy P. Hughes(Royal Adelaide Hospital), John Reynolds(The Alfred Hospital), Anthony K. Mills(Princess Alexandra Hospital), Jake Shortt(The University of Melbourne), David Kipp(Geelong Hospital), Agnes S. M. Yong(South Australia Pathology), Andrew Grigg(The Royal Melbourne Hospital), Ilona Cunningham(The University of Sydney), Robert Weinkove(Malaghan Institute of Medical Research), Anthony P. Schwarer(The Alfred Hospital), Nicholas Viiala(Liverpool Hospital)
Cited by 7
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464